AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30801994 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 23735
Study 30801994 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score model
Number of subjects: 23735
Study 27789350 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPA 75 mg
Number of subjects: 34
Study 27789350 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPA 104 mg
Number of subjects: 34
Study 27789350 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPA 150 mg
Number of subjects: 34
Study 27789350 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 34
Study 24691155 — intervention group
Group type: EXPERIMENTAL
Intervention: Life-review
Number of subjects: 58
Study 24691155 — intervention group
Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 58
Study 24691155 — intervention group
Group type: COMPARATOR
Intervention: Expressive writing
Number of subjects: 58
Study 23632801 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolift procedure
Number of subjects: 67
Study 23632801 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-POP patients)
Number of subjects: 67
Study 21767360 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight management program with body image module
Number of subjects: 239
Study 19489898 — intervention group
Group type: EXPERIMENTAL
Intervention: Literacy Express Preschool Curriculum in English‐only (n = 31)
Number of subjects: 94
Study 19489898 — intervention group
Group type: EXPERIMENTAL
Intervention: Literacy Express Preschool Curriculum initially in Spanish transitioning to English (n = 31)
Number of subjects: 94
Study 19489898 — intervention group
Group type: COMPARATOR
Intervention: High/Scope Curriculum (control n = 32)
Number of subjects: 94
Study 17724529 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazol 40 mg/day for 12 weeks
Number of subjects: 49
Study 17724529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 15294061 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation with noseclip
Number of subjects: 10
Study 15294061 — intervention group
Group type: COMPARATOR
Intervention: Inhalation without noseclip
Number of subjects: 10
Study 11531216 — intervention group
Group type: EXPERIMENTAL
Intervention: Trophic feedings from day 4 through 14
Number of subjects: 171
Study 11531216 — intervention group
Group type: COMPARATOR
Intervention: Standard feedings starting at day 15
Number of subjects: 171
Study 11531216 — intervention group
Group type: EXPERIMENTAL
Intervention: Trophic feedings
Number of subjects: 171
Study 11531216 — intervention group
Group type: COMPARATOR
Intervention: Standard feedings
Number of subjects: 171
Study 11531216 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus feedings
Number of subjects: 171
Study 11531216 — intervention group
Group type: COMPARATOR
Intervention: Continuous feedings
Number of subjects: 171
Study 9760817 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX)
Number of subjects: 14
Study 9760817 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pentoxifylline)
Number of subjects: 14
Study 8310978 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg once daily
Number of subjects: 29
Study 3131884 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 30 micrograms/kg
Number of subjects: 39
Study 3131884 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 5 micrograms/kg
Number of subjects: 39
Study 3131884 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lignocaine 2 mg/kg
Number of subjects: 39
Study 3131884 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 10% spray 2 mg/kg to the larynx
Number of subjects: 39
Study 30910500 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day educational workshop on patient safety
Number of subjects: 90
Study 30910500 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 90
Study 28818255 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid revascularization and intensive medical management
Number of subjects: 0
Study 28818255 — intervention group
Group type: COMPARATOR
Intervention: Medical management alone
Number of subjects: 0
Study 28818255 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid stenting with embolic protection
Number of subjects: 0
Study 28818255 — intervention group
Group type: COMPARATOR
Intervention: No stenting
Number of subjects: 0
Study 24960435 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Navigation (PN) with facilitated enrollment into an indigent care discount program
Number of subjects: 40
Study 24960435 — intervention group
Group type: COMPARATOR
Intervention: Facilitated enrollment into an indigent care discount program alone (Control)
Number of subjects: 40
Study 24432037 — intervention group
Group type: EXPERIMENTAL
Intervention: Avanafil (200 mg)
Number of subjects: 106
Study 24432037 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (100 mg)
Number of subjects: 106
Study 24432037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 24432037 — intervention group
Group type: EXPERIMENTAL
Intervention: Avanafil (200 mg) 0.5 hours before NTG
Number of subjects: 106
Study 24432037 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (100 mg) 0.5 hours before NTG
Number of subjects: 106
Study 24432037 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (100 mg) 1 hour before NTG
Number of subjects: 106
Study 24432037 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (100 mg) 12 hours before NTG
Number of subjects: 106
Study 20810219 — intervention group
Group type: EXPERIMENTAL
Intervention: 17β‐estradiol (E)
Number of subjects: 53
Study 20810219 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone‐plus‐estrogen
Number of subjects: 53
Study 20810219 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen therapies unopposed by progesterone
Number of subjects: 53
Study 20810219 — intervention group
Group type: COMPARATOR
Intervention: Estrogen‐containing hormone therapy
Number of subjects: 53
Study 19594262 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored print-based fruit and vegetable intervention on ethnic identity
Number of subjects: 560
Study 19594262 — intervention group
Group type: COMPARATOR
Intervention: Control condition (demographic and social cognitive variables only)
Number of subjects: 560
Study 19594262 — intervention group
Group type: EXPERIMENTAL
Intervention: Afrocentric experimental group
Number of subjects: 560
Study 19594262 — intervention group
Group type: COMPARATOR
Intervention: Afrocentric control group
Number of subjects: 560
Study 16708724 — intervention group
Group type: EXPERIMENTAL
Intervention: Ormocer or nanofill composite with flowable liner (Admira Flow or Filtek Flow)
Number of subjects: 54
Study 16708724 — intervention group
Group type: COMPARATOR
Intervention: Ormocer or nanofill composite without flowable liner
Number of subjects: 54
Study 12688320 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methylprednisolone (HDMP) in Group B1
Number of subjects: 194
Study 12688320 — intervention group
Group type: COMPARATOR
Intervention: Conventional dose steroids in Group A2 and A3
Number of subjects: 194
Study 10902981 — intervention group
Group type: EXPERIMENTAL
Intervention: Condensed milk + micronutrients
Number of subjects: 0
Study 10902981 — intervention group
Group type: EXPERIMENTAL
Intervention: Skimmed milk + micronutrients
Number of subjects: 0
Study 10902981 — intervention group
Group type: COMPARATOR
Intervention: Skimmed milk
Number of subjects: 0
Study 9042991 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide, 50 microg, subcutaneous injection 5 min before ingestion of a test meal
Number of subjects: 20
Study 9042991 — intervention group
Group type: COMPARATOR
Intervention: Placebo, subcutaneous injection 5 min before ingestion of a test meal
Number of subjects: 20
Study 9042991 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide with solid meal
Number of subjects: 20
Study 9042991 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide with liquid meal
Number of subjects: 20
Study 1607272 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine bisulphate 500 mg from Teva
Number of subjects: 7
Study 1607272 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine bisulphate 250 mg from Teva
Number of subjects: 7
Study 1607272 — intervention group
Group type: COMPARATOR
Intervention: Short-acting quinidine sulphate 200 mg
Number of subjects: 7
Study 3896583 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromhexine (Bisolvon)
Number of subjects: 95
Study 3896583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 30091064 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month home exercise program
Number of subjects: 141
Study 30091064 — intervention group
Group type: COMPARATOR
Intervention: Equal attention control group
Number of subjects: 141
Study 27636753 — intervention group
Group type: COMPARATOR
Intervention: Local anti-inflammatory therapy
Number of subjects: 35
Study 27636753 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention on the periodontium in addition to local anti-inflammatory therapy
Number of subjects: 35
Study 24837707 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal exercise-based cardiac rehabilitation (CR) with exercise prescription based on exercise testing
Number of subjects: 383096
Study 24837707 — intervention group
Group type: COMPARATOR
Intervention: Non-formal exercise-based cardiac rehabilitation (CR) without exercise prescription
Number of subjects: 383096
Study 24837707 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise testing sessions
Number of subjects: 383096
Study 21695708 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.18 W/kg exposure
Number of subjects: 16
Study 21695708 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 W/kg exposure
Number of subjects: 16
Study 21695708 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 16
Study 21695708 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.18 W/kg and 1.8 W/kg exposures
Number of subjects: 16
Study 21695708 — intervention group
Group type: EXPERIMENTAL
Intervention: Other parameters
Number of subjects: 16
Study 20485708 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 20485708 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 16954654 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast 1,000 microg
Number of subjects: 13
Study 16954654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 15709892 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 439
Study 15709892 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine + Cognitive Behavioural Therapy (CBT)
Number of subjects: 439
Study 15709892 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioural Therapy (CBT) alone
Number of subjects: 439
Study 15709892 — intervention group
Group type: COMPARATOR
Intervention: No Fluoxetine (placebo)
Number of subjects: 439
Study 12067044 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention (20% energy from fat)
Number of subjects: 13277
Study 10485771 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular rocuronium (1 mg/kg for infants, 1.8 mg/kg for children)
Number of subjects: 76
Study 10485771 — intervention group
Group type: COMPARATOR
Intervention: Intravenous rocuronium (0.45 mg/kg)
Number of subjects: 76
Study 10485771 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular rocuronium
Number of subjects: 76
Study 8938532 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin (1000 or 1200 mg/day for 24 weeks)
Number of subjects: 114
Study 1936497 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 600 mg orally
Number of subjects: 50
Study 1936497 — intervention group
Group type: COMPARATOR
Intervention: Vacuum aspiration
Number of subjects: 50
Study 1936497 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 1936497 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone
Number of subjects: 50
Study 7332739 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 8
Study 7332739 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE2)
Number of subjects: 8
Study 7332739 — intervention group
Group type: COMPARATOR
Intervention: Ethanol/saline mixture (diluent of PGE2)
Number of subjects: 8
Study 31292301 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin treatment
Number of subjects: 4991
Study 30305146 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised target effect size
Number of subjects: 107
Study 30305146 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised observed effect size
Number of subjects: 107
Study 30305146 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum anticipated effect size
Number of subjects: 107
Study 30305146 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum observed effect size
Number of subjects: 107
Study 30305146 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipated target values
Number of subjects: 107
Study 26962078 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam plus metronidazole
Number of subjects: 1066
Study 26962078 — intervention group
Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 1066
Study 25210879 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of GLP‐1 (0.9 pmol/kg/min)
Number of subjects: 10
Study 25210879 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.9%)
Number of subjects: 10
Study 23234759 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive site
Number of subjects: 8112
Study 23234759 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized-supportive site
Number of subjects: 8112
Study 23234759 — intervention group
Group type: COMPARATOR
Intervention: Information-based site
Number of subjects: 8112
Study 23234759 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 8112
Study 23234759 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive conditions
Number of subjects: 8112
Study 21177352 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labour
Number of subjects: 650
Study 21177352 — intervention group
Group type: COMPARATOR
Intervention: Expectant monitoring
Number of subjects: 650
Study 17512607 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5-20 mg/day)
Number of subjects: 0
Study 17512607 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine-Fluoxetine Combination (OFC) (6/25, 6/50, or 12/50 mg/day)
Number of subjects: 0
Study 17512607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17512607 — intervention group
Group type: EXPERIMENTAL
Intervention: OFC
Number of subjects: 0
Study 17512607 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study 16306819 — intervention group
Group type: EXPERIMENTAL
Intervention: Single visit (SV group, n = 20)
Number of subjects: 50
Study 16306819 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide for one week (CH group, n = 18)
Number of subjects: 50
Study 16306819 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaving the canal empty but sealed for one week (EC group, n = 12)
Number of subjects: 50
Study 16306819 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite irrigation
Number of subjects: 50
Study 16306819 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial growth at the second appointment
Number of subjects: 50
Study 16306819 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide dressing
Number of subjects: 50
Study 12210784 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ischemic forearm exercise test
Number of subjects: 19
Study 12210784 — intervention group
Group type: COMPARATOR
Intervention: Ischemic forearm exercise test
Number of subjects: 19
Study 10325560 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeons' decision
Number of subjects: 344
Study 10325560 — intervention group
Group type: COMPARATOR
Intervention: Adjudication process
Number of subjects: 344
Study 7572707 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil diet (40% fat, 22% MUFAs)
Number of subjects: 21
Study 7572707 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunflower oil diet (40% fat, 22% MUFAs)
Number of subjects: 21
Study 7572707 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil diet
Number of subjects: 21
Study 7572707 — intervention group
Group type: COMPARATOR
Intervention: NCEP-I diet
Number of subjects: 21
Study 1673975 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (15 mg single dose)
Number of subjects: 10
Study 1673975 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (15 mg twice daily for 7 days)
Number of subjects: 10
Study 1673975 — intervention group
Group type: COMPARATOR
Intervention: Placebo (single dose)
Number of subjects: 10
Study 1673975 — intervention group
Group type: COMPARATOR
Intervention: Placebo (7 days treatment)
Number of subjects: 10
Study 1673975 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (single dose)
Number of subjects: 10
Study 1673975 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (7 days treatment)
Number of subjects: 10
Study 7284885 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 ml of bupivacaine 0.25 per cent
Number of subjects: 131
Study 7284885 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 ml of bupivacaine 0.5 per cent
Number of subjects: 131
Study 7284885 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral position maintained after induction
Number of subjects: 131
Study 7284885 — intervention group
Group type: EXPERIMENTAL
Intervention: Turning to the contralateral side after injection of 12 ml bupivacaine 0.25 per cent
Number of subjects: 131
Study 31570470 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 125
Study 31570470 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 125
Study 31570470 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin (control)
Number of subjects: 125
Study 29130655 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacroiliac joint dislocation with anterior plate fixation (Group A)
Number of subjects: 50
Study 29130655 — intervention group
Group type: COMPARATOR
Intervention: Computerized navigation for percutaneous sacroiliac screw (Group B)
Number of subjects: 50
Study 29130655 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (Group A and Group B)
Number of subjects: 50
Study 25962875 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cannabis puffs (1-12 puffs, $0.25-$5/puff)
Number of subjects: 21
Study 25962875 — intervention group
Group type: COMPARATOR
Intervention: Placebo cannabis puffs (1-12 puffs, $0.25-$5/puff)
Number of subjects: 21
Study 23536259 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention (not specified in detail)
Number of subjects: 73
Study 23536259 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 73
Study 21793047 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT) via video teleconferencing (VT)
Number of subjects: 13
Study 21793047 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Processing Therapy (CPT) in-person modality
Number of subjects: 13
Study 19119164 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiBond Solo (OS), filled, ethanol‐based adhesive
Number of subjects: 33
Study 19119164 — intervention group
Group type: COMPARATOR
Intervention: Prime & Bond 2.1 (PB), unfilled, acetone‐based adhesive
Number of subjects: 33
Study 17159194 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin alone for 24 months
Number of subjects: 874
Study 17159194 — intervention group
Group type: COMPARATOR
Intervention: CMF chemotherapy
Number of subjects: 874
Study 17159194 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF followed by goserelin for 18 months
Number of subjects: 874
Study 17159194 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin alone for younger patients (< 40 years)
Number of subjects: 874
Study 17159194 — intervention group
Group type: COMPARATOR
Intervention: CMF for younger patients (< 40 years)
Number of subjects: 874
Study 10967604 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg ascorbic acid
Number of subjects: 30
Study 10967604 — intervention group
Group type: EXPERIMENTAL
Intervention: 73.5 mg RRR‐alpha‐tocopherol acetate
Number of subjects: 30
Study 10967604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8695075 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 0.75 mg/kg
Number of subjects: 90
Study 8695075 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine 1 mg/kg
Number of subjects: 90
Study 8695075 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 90
Study 1512911 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial ileal bypass operation
Number of subjects: 838
Study 1512911 — intervention group
Group type: COMPARATOR
Intervention: American Heart Association Phase II diet instruction
Number of subjects: 838
Study 1512911 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall disease assessment
Number of subjects: 838
Study 6434081 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D2 25 micrograms daily
Number of subjects: 41
Study 6434081 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol 0.5 micrograms daily
Number of subjects: 41
Study 6434081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 30273590 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue-light imaging (BLI)
Number of subjects: 245
Study 30273590 — intervention group
Group type: COMPARATOR
Intervention: High-definition white light (HDWL)
Number of subjects: 245
Study 30328511 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography screening
Number of subjects: 0
Study 30328511 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorectal and cervical cancer screening
Number of subjects: 0
Study 30328511 — intervention group
Group type: COMPARATOR
Intervention: Randomized controlled trial (RCT)
Number of subjects: 0
Study 26325166 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting state
Number of subjects: 0
Study 26325166 — intervention group
Group type: COMPARATOR
Intervention: Fed state
Number of subjects: 0